Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 107

Similar articles for PubMed (Select 22144567)

1.

Using stress testing to guide primary prevention of coronary heart disease among intermediate-risk patients: a cost-effectiveness analysis.

Galper BZ, Moran A, Coxson PG, Pletcher MJ, Heidenreich P, Lazar LD, Rodondi N, Wang YC, Goldman L.

Circulation. 2012 Jan 17;125(2):260-70. doi: 10.1161/CIRCULATIONAHA.111.041293. Epub 2011 Dec 5.

2.

Aspirin, statins, or both drugs for the primary prevention of coronary heart disease events in men: a cost-utility analysis.

Pignone M, Earnshaw S, Tice JA, Pletcher MJ.

Ann Intern Med. 2006 Mar 7;144(5):326-36.

PMID:
16520473
3.

Comparing impact and cost-effectiveness of primary prevention strategies for lipid-lowering.

Pletcher MJ, Lazar L, Bibbins-Domingo K, Moran A, Rodondi N, Coxson P, Lightwood J, Williams L, Goldman L.

Ann Intern Med. 2009 Feb 17;150(4):243-54.

PMID:
19221376
4.

Using the coronary artery calcium score to guide statin therapy: a cost-effectiveness analysis.

Pletcher MJ, Pignone M, Earnshaw S, McDade C, Phillips KA, Auer R, Zablotska L, Greenland P.

Circ Cardiovasc Qual Outcomes. 2014 Mar;7(2):276-84. doi: 10.1161/CIRCOUTCOMES.113.000799. Epub 2014 Mar 11.

5.

Cost-effectiveness of providing full drug coverage to increase medication adherence in post-myocardial infarction Medicare beneficiaries.

Choudhry NK, Patrick AR, Antman EM, Avorn J, Shrank WH.

Circulation. 2008 Mar 11;117(10):1261-8. doi: 10.1161/CIRCULATIONAHA.107.735605. Epub 2008 Feb 19.

6.

A systematic review and economic evaluation of statins for the prevention of coronary events.

Ward S, Lloyd Jones M, Pandor A, Holmes M, Ara R, Ryan A, Yeo W, Payne N.

Health Technol Assess. 2007 Apr;11(14):1-160, iii-iv. Review.

7.

Summaries for patients. The cost-effectiveness of aspirin, statins, or both drugs in the primary prevention of heart disease.

[No authors listed]

Ann Intern Med. 2006 Mar 7;144(5):I29. No abstract available.

PMID:
16520469
8.

Cost-effectiveness of optimal use of acute myocardial infarction treatments and impact on coronary heart disease mortality in China.

Wang M, Moran AE, Liu J, Coxson PG, Heidenreich PA, Gu D, He J, Goldman L, Zhao D.

Circ Cardiovasc Qual Outcomes. 2014 Jan;7(1):78-85. doi: 10.1161/CIRCOUTCOMES.113.000674. Epub 2014 Jan 14.

9.

Economic analysis of treatments reducing coronary heart disease mortality in England and Wales, 2000-2010.

Fidan D, Unal B, Critchley J, Capewell S.

QJM. 2007 May;100(5):277-89. Epub 2007 Apr 21.

10.

Cost-effectiveness of cholesterol-lowering therapies according to selected patient characteristics.

Prosser LA, Stinnett AA, Goldman PA, Williams LW, Hunink MG, Goldman L, Weinstein MC.

Ann Intern Med. 2000 May 16;132(10):769-79.

PMID:
10819699
11.
12.

Cost-effectiveness of diagnostic strategies for patients with chest pain.

Kuntz KM, Fleischmann KE, Hunink MG, Douglas PS.

Ann Intern Med. 1999 May 4;130(9):709-18.

PMID:
10357689
13.

Cost effectiveness of aspirin, clopidogrel, or both for secondary prevention of coronary heart disease.

Gaspoz JM, Coxson PG, Goldman PA, Williams LW, Kuntz KM, Hunink MG, Goldman L.

N Engl J Med. 2002 Jun 6;346(23):1800-6.

14.

Cost-utility of aspirin and proton pump inhibitors for primary prevention.

Earnshaw SR, Scheiman J, Fendrick AM, McDade C, Pignone M.

Arch Intern Med. 2011 Feb 14;171(3):218-25. doi: 10.1001/archinternmed.2010.525.

15.

Cost-effectiveness of alternative test strategies for the diagnosis of coronary artery disease.

Garber AM, Solomon NA.

Ann Intern Med. 1999 May 4;130(9):719-28.

PMID:
10357690
16.

Statins for cardiovascular prevention according to different strategies: a cost analysis.

Ito MK, Nanchen D, Rodondi N, Paccaud F, Waeber G, Vollenweider P, Marques-Vidal P.

Am J Cardiovasc Drugs. 2011;11(1):33-44. doi: 10.2165/11586760-000000000-00000.

PMID:
21265581
17.

Statin treatment for primary prevention of vascular disease: whom to treat? Cost-effectiveness analysis.

Greving JP, Visseren FL, de Wit GA, Algra A.

BMJ. 2011 Mar 30;342:d1672. doi: 10.1136/bmj.d1672.

18.

Cost effectiveness of statins for the secondary prevention of coronary heart disease in Ireland.

Barry M, Heerey A.

Ir Med J. 2002 May;95(5):133-5. No abstract available.

PMID:
12092692
19.

Incremental benefit and cost-effectiveness of high-dose statin therapy in high-risk patients with coronary artery disease.

Chan PS, Nallamothu BK, Gurm HS, Hayward RA, Vijan S.

Circulation. 2007 May 8;115(18):2398-409. Epub 2007 Apr 23.

20.

Cost-effectiveness of HMG coenzyme reductase inhibitors; whom to treat?

van Hout BA, Simoons ML.

Eur Heart J. 2001 May;22(9):751-61.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk